You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Teprotumumab-trbw - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


Summary for teprotumumab-trbw
Tradenames:1
High Confidence Patents:0
Applicants:1
BLAs:1
Suppliers: see list1
Pharmacology for teprotumumab-trbw
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for teprotumumab-trbw Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for teprotumumab-trbw Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for teprotumumab-trbw Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Teprotumumab-trbw (Tepezza)

Introduction

Teprotumumab-trbw, marketed as Tepezza, is a groundbreaking biologic drug approved by the FDA for the treatment of Thyroid Eye Disease (TED), a rare and debilitating autoimmune condition. This article delves into the market dynamics and financial trajectory of Tepezza, highlighting its efficacy, market impact, and financial performance.

Efficacy and Clinical Significance

Tepezza is the first and only FDA-approved medication for TED, a condition that can lead to severe vision impairment and facial disfigurement. The drug works by inhibiting the insulin-like growth factor-1 receptor (IGF-1R), a key mediator of TED, thereby reducing inflammation and reversing retro-orbital tissue expansion[2][3].

Clinical trials have demonstrated the efficacy of Tepezza in reducing proptosis (bulging of the eyes) and improving visual functioning. In a Phase 4 clinical trial, patients treated with Tepezza showed a significant reduction in proptosis and improvement in visual functioning compared to the placebo group[2].

Market Approval and Regulatory Considerations

Tepezza received FDA approval in 2020, marking a significant milestone in the treatment of TED. The drug was granted Priority Review, Orphan Drug, Fast Track, and Breakthrough Therapy designations, reflecting its potential to address a critical unmet medical need[5].

Market Supply and Manufacturing

Following its approval, Tepezza faced a supply disruption due to COVID-19-related manufacturing priorities. However, Horizon Therapeutics, the manufacturer, secured FDA approval for a prior approval supplement to increase production, ensuring a steady supply of the drug starting from April 2021[4].

Financial Performance

The financial trajectory of Tepezza has been robust. Horizon Therapeutics anticipated full-year 2021 net sales of more than $1.275 billion for Tepezza, indicating strong market demand and adoption[4].

Revenue Projections

The revenue projections for Tepezza are substantial, driven by its unique position as the only FDA-approved treatment for TED. The drug's high cost, with a single vial priced at approximately $14,900 and total treatment costs ranging from $200,000 to $480,000, contributes significantly to its revenue[1].

Market Expansion

Horizon Therapeutics is expanding its clinical trials for Tepezza, including studies in chronic TED and diffuse cutaneous systemic sclerosis. These trials are expected to further establish the drug's efficacy and safety profile, potentially expanding its market reach[4].

Access and Affordability

Despite its efficacy, access to Tepezza is influenced by several socioeconomic factors. Insurance type, geographic location, and socioeconomic status can affect the approval of prior authorizations for the drug. Medicare members are more likely to be approved for treatment compared to those with Medi-Cal coverage. The high cost of Tepezza remains a significant barrier for uninsured patients[1].

Impact on Patient Care

The introduction of Tepezza has significantly improved the care for TED patients. Home infusion settings have been successfully implemented to minimize the risk of COVID-19 infection, ensuring continuous treatment during the pandemic[5].

Quality of Life

Tepezza has shown to improve visual functioning and overall quality of life for TED patients. The Graves’ Ophthalmopathy Quality of Life Questionnaire (GO-QOL) has been used to measure these improvements, highlighting the drug's positive impact on patients' daily lives[2].

Market Dynamics and Competition

The market for TED treatments is relatively niche due to the rarity of the disease. However, the approval of Tepezza has brought significant attention to this area, encouraging further research and development in ocular diseases. The lack of alternative FDA-approved treatments for TED gives Tepezza a dominant market position[3].

Challenges and Future Directions

While Tepezza has revolutionized TED treatment, several challenges remain. The high cost and complex prior authorization process can limit access. Ongoing research and clinical trials aim to expand the drug's indications and improve its accessibility.

Regulatory and Clinical Trials

Future clinical trials, including those in chronic TED and other conditions, will be crucial in expanding Tepezza's market. Regulatory updates and guidelines can also streamline the authorization process, making the drug more accessible to patients[2][4].

Key Takeaways

  • Efficacy: Tepezza has demonstrated significant efficacy in reducing proptosis and improving visual functioning in TED patients.
  • Market Approval: FDA approval in 2020 marked a critical milestone, with the drug receiving several designations for its potential to address unmet medical needs.
  • Financial Performance: Strong revenue projections, with anticipated full-year 2021 net sales exceeding $1.275 billion.
  • Access and Affordability: Socioeconomic factors and high costs affect access, with ongoing efforts to streamline prior authorizations.
  • Impact on Patient Care: Improvements in quality of life and successful home infusion settings during the pandemic.

FAQs

Q: What is Tepezza used for?

A: Tepezza (teprotumumab-trbw) is used for the treatment of Thyroid Eye Disease (TED), a rare autoimmune condition that can cause vision impairment and facial disfigurement.

Q: How does Tepezza work?

A: Tepezza works by inhibiting the insulin-like growth factor-1 receptor (IGF-1R), which is a key mediator of TED, thereby reducing inflammation and reversing retro-orbital tissue expansion.

Q: What are the clinical trial results for Tepezza?

A: Clinical trials have shown that Tepezza significantly reduces proptosis and improves visual functioning in TED patients compared to the placebo group.

Q: Why is access to Tepezza limited for some patients?

A: Access to Tepezza can be limited due to socioeconomic factors such as insurance type, geographic location, and high treatment costs.

Q: What are the future directions for Tepezza?

A: Ongoing clinical trials aim to expand Tepezza's indications, including studies in chronic TED and diffuse cutaneous systemic sclerosis, and efforts to streamline prior authorizations to improve accessibility.

Sources

  1. Trends in Teprotumumab Insurance Authorization and ... - Journal of Ophthalmology and Eye Diseases
  2. Data from phase 4 clinical trial for teprotumumab-trbw presented at ... - Ophthalmology Times
  3. Thyroid Eye Disease: Rare Disease Drug Development ... - Certara
  4. Horizon Therapeutics plc to Resupply Market With TEPEZZA ... - Business Wire
  5. Home Infusion of Thyroid Eye Disease Treatment Shows Efficacy of ... - Pharmacy Times

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.